Literature DB >> 19920093

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study).

Salvatore Scarpato1, Marco Antivalle, Ennio G Favalli, Francesca Nacci, Sabrina Frigelli, Francesca Bartoli, Laura Bazzichi, Giovanni Minisola, Marco Matucci Cerinic.   

Abstract

OBJECTIVE: To identify the determinants of anti-TNF-naive patients' preferences for the route of administration of anti-TNF agents.
METHODS: The study was carried out in 50 Italian rheumatology centres (802 patients). All patients completed a 31-item questionnaire addressing their perceptions of current treatment and the preferences for treatment with anti-TNF agents. Statistical methods included analysis of variance (ANOVA), t-test and chi-square test.
RESULTS: The response rate to the questionnaire was 97.6%. At the time of the survey, 310 (39.9%) patients were dissatisfied with current treatments, owing to inefficacy, side effects and inconvenience of administration. The i.v. and s.c. routes of administration were preferred by 50.2 and 49.8%, respectively. No significant difference was found in patients by gender, age, RA duration or number of drugs used. Reasons for the choice of i.v. administration were the safety of treatment at the hospital and the reassuring effect of physician presence. The s.c. administration was chosen for the convenience of treatment and in particular for home treatment. Patients dissatisfied with current therapy due to side effects preferred s.c. administration (P = 0.029), whereas patients choosing the i.v. route had slightly higher scores on 'today pain' (P = 0.047) and 'articular pain' (P = 0.023) of the Rheumatoid Arthritis Disease Activity Index (RADAI).
CONCLUSIONS: Both i.v. and s.c. treatments were well accepted by patients. However, treatment choice has to be discussed with patients, as individual preference seems to be determined by personal attitudes towards safety and convenience, by past experience and by the perception of current disease status.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920093     DOI: 10.1093/rheumatology/kep354

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  32 in total

Review 1.  Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians.

Authors:  Majed M Khraishi
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

2.  Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.

Authors:  Marie Desplats; Tristan Pascart; Germain Jelin; Laurène Norberciak; Peggy Philippe; Eric Houvenagel; Vincent Goeb; René-Marc Flipo
Journal:  Clin Rheumatol       Date:  2017-03-02       Impact factor: 2.980

3.  Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options.

Authors:  Gosia Sylwestrzak; Jinan Liu; Judith J Stephenson; Alexander P Ruggieri; Andrea DeVries
Journal:  Am Health Drug Benefits       Date:  2014-04

Review 4.  Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.

Authors:  R W Stidham; T C H Lee; P D R Higgins; A R Deshpande; D A Sussman; A G Singal; B J Elmunzer; S D Saini; S Vijan; A K Waljee
Journal:  Aliment Pharmacol Ther       Date:  2014-04-20       Impact factor: 8.171

5.  Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.

Authors:  Kelly L Stoner; Helena Harder; Lesley J Fallowfield; Valerie A Jenkins
Journal:  Patient       Date:  2014-07-12       Impact factor: 3.883

Review 6.  Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis.

Authors:  Despoina Dimopoulou; Theodoros Dimitroulas; Evangelos Akriviadis; Alexandros Garyfallos
Journal:  Rheumatol Int       Date:  2015-09-28       Impact factor: 2.631

7.  Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis.

Authors:  U Müller-Ladner; R M Flipo; P Vincendon; Y Brault; D Kielar
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

Review 8.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

9.  Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns.

Authors:  Louisa Voight
Journal:  Patient Prefer Adherence       Date:  2012-04-10       Impact factor: 2.711

10.  Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.

Authors:  D E Furst; S A Shaikh; M Greenwald; B Bennett; O Davies; K Luijtens; F Staelens; W Koetse; P Bertin
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-02       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.